DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017 September 6, 2017 • 1:59 PM EDT
DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM July 24, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM July 18, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman July 11, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Joins National Brain Tumor Society's Research Roundtable June 29, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM June 22, 2017 • 8:30 AM EDT
DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma ("GBM") at SNO's Pediatric Neuro-Oncology Basic and Translational Research Conference June 16, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results May 18, 2017 • 5:13 PM EDT
DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM) May 11, 2017 • 8:30 AM EDT
DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS) May 8, 2017 • 8:30 AM EDT